Talpaz M, Kurzrock R, Kantarjian H, Gutterman J
University of Texas M.D. Anderson Cancer Center, Houston 77030.
Cancer Surv. 1989;8(4):793-8.
Therapy of Philadelphia positive chronic myelogenous leukaemia (CML Ph1) with alpha interferon (IFN-alpha) resulted in a high frequency of haematological remissions. Effective suppression of the malignant Ph1 clone and concomitant partial or complete restoration of normal haemopoiesis is reproducibly noted in a proportion (30%-50%) of the patients. This and the low incidence of blast crisis underscore the profound effect this therapy has on the disease. Marked heterogeneity in the response to IFN-alpha was noted as well, and sensitivity or resistance to interferon was phenotypically indistinguishable. Studies of the IFN-resistant disease failed to disclose alteration in IFN receptors or in IFN-inducible genes and are suggestive, therefore, of a limited alteration in IFN-induced intracellular pathways.
用α干扰素（IFN-α）治疗费城染色体阳性的慢性粒细胞白血病（CML Ph1）可产生高频率的血液学缓解。在一定比例（30%-50%）的患者中可反复观察到恶性Ph1克隆被有效抑制，同时正常造血功能部分或完全恢复。这一点以及急变期的低发生率突出了该疗法对疾病的深远影响。对IFN-α的反应也存在明显的异质性，对干扰素的敏感性或耐药性在表型上无法区分。对IFN耐药疾病的研究未能揭示IFN受体或IFN诱导基因的改变，因此提示IFN诱导的细胞内信号通路改变有限。
